BEGIN:VCALENDAR
VERSION:2.0
PRODID:Spatie calendar-links
BEGIN:VEVENT
UID:5f5320662199300e117aa57fbf6ece38
SUMMARY:Visual Abstracts Friday\n\n
DTSTAMP:20240913T080000Z
DTSTART:20240913T080000Z
DTEND:20240913T083000Z
DESCRIPTION:Visual Abstracts Friday\n\n\n\nPresentations:\n\nAnalytical Performance of a Novel\, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Detection of 15 antibodies Associated with CTD\nReferent(s): G. Gomez\, Eysins (CH)\; D. Bijlsma\, Eysins (CH)\; E. Lukasik\, Eysins (CH)\; M. Hausmann\, Eysins (CH)\; C. Fischer\, Eysins (CH)\; P. Ghillani-Dalbin\, Paris (FR)\; M. Miyara\, Paris (FR)\; E. Moreau\, Eysins (CH)\n\nA Swiss Model of Collaborative Care for Patients with&nbsp\;Immunodeficiency by Integrating Specialized Private Practice and University Center Expertise\nReferent(s): O. V. Hausmann\, Luzern (CH)\; M. Kühn\, Luzern (CH)\; F. Poletti\, Basel (CH)\; J. Köppen\, Basel (CH)\; M. Recher\, Basel (CH)\n\nUnderstanding the connections between cellular metabolism\, MHCI regulation\, and the immune response\nReferent(s): S. Nakka\, Bellinzona (CH)\; G. Guarda\, Bellinzona (CH)\; A. Zenobi\, Bellinzona (CH)\; H. Khameneh\, Bellinzona (CH)\; A. Rinaldi\, Bellinzona (CH)\; B. Fischer\, Stockholm (SE)\n\nHuman-plasma derived-IgG and recombinant IgG Fc fragments modulate the effector functions of NK cells\nReferent(s): D. Reis Galvão\, Geneva (CH)\; M. Freitas Monteiro\, Geneva (CH)\; R. Spirig\, Bern (CH)\; G. Puga Yung\, Geneva (CH)\; J. D. Seebach\, Geneva (CH)\n\nSphingomyelin complexed cholesterol controls Lymphocyte function-associated antigen-1 mediated effector T cell function.\nReferent(s): K. Patommel\, Cambridge (GB)\; A. A. Martí I Líndez\, Cambridge (GB)\; J. Jaenicke\, Cambridge (GB)\; S. Verma\, Cambridge (GB)\; J. Edwards-Hicks\, Edinburgh (GB)\; C. Hess\, Basel (CH)\; L. Laraia\, Kongens Lyngby (DK)\; S. Wilson\, Cambridge (GB)\; M. Donde\, Cambridge (GB)\; J. Lötscher\, Basel (CH)\; L. M. Booty\, Stevenage\n\nHigh-affinity omalizumab variants with optimized disruptive efficacy accelerate allergic effector cell desensitization\nReferent(s): A. Eggel\, Bern (CH)\; L. Pennington\, Stanford (US)\; D. Brigger\, Bern (CH)\; R. Van Brummelen\, Bern (CH)\; P. Guntern\, Bern (CH)\; T. Jardetzky\, Stanford (US)\n\nBlunting of CD8+ T cell response to COVID-19 mRNA vaccine in JAK inhibitor-treated patients is associated with reduced interferon signaling.\nReferent(s): N. Madelon\, Genève (CH)\; N. Heikkila\, Geneva (CH)\; R. Morse\, Geneva (CH)\; G. Ruiz Buendia\, Genève (CH)\; P. Girard\, Geneva (CH)\; W. Adouan\, Geneva (CH)\; P. Fontannaz\, Geneva (CH)\; R. Goldstein\, Geneva (CH)\; K. Lauper\, Geneva (CH)\; A. Finkch\, Geneve (CH)\; C. Eberhardt\, Genève (CH)\; C. Berger\, Basel (CH)\; A. Didierlaurent\, Genève (CH)\n\nEffect of radiotherapy on the immune microenvironment of muscle-invasive bladder cancer\nReferent(s): G. Zanette\, Lausanne (CH)\; E. Desponds\, Lausanne (CH)\; M. Leblond\, Lausanne (CH)\; V. Grégory\, Lausanne (CH)\n\nHigh-resolution KIR genotyping and its implication in allogeneic hematopoietic stem cell transplantation\nReferent(s): A. Schäfer\, Genève (CH)\; J. Villard\, Genève (CH)\; S. Buhler\, Geneva (CH)\; T. Farias\, Colorado (US)\; K. Kichula\, Colorado (US)\; Z. Calderin Sollet\, Geneva (CH)\; M. P. Hervé\, Geneva (CH)\; S. Ferrari-Lacraz\, Geneva (CH)\; Y. Chalandon\, Geneva (CH)\; S. Masouridi\, Geneva (CH)\; D. Schneidawind\, Zurich (CH)\; V. Mesquita\, Zurich (CH)\; T. Gungor\, Zurich (CH)\; O. Kursteiner\, Liebefeld (CH)\; G. Nair\, Liebefeld (CH)\; J. Halter\, Basel (CH)\; H. Baldomero\, Basel (CH)\; J. Passweg\, Basel (CH)\; P. Norman\, Colorado (US)\n\nAntigen recycling in mast cells for the regulation of the immune response\nReferent(s): J. Miguez Vazquez\, Bern (CH)\; P. Engeroff\, Bern (CH)\; M. Vogel\, Bern (CH)\; M. Bachmann\, Bern (CH)\n\nTransglutaminase 2 governs phospholipid metabolism and ferroptosis in type 2 immunity\nReferent(s): B. Spitzlberger\, Munich (DE)\; J. Esser-Von-Bieren\, Lausanne (CH)\; F. D. Henkel\, Munich (DE)\; E. Ben Salah\, Epalinges (CH)\; R. Zhigang\, Innsbruck (AT)\; S. Bohnacker\, Epalinges (CH)\; S. Schindela\, Munich (DE)\; F. Hartung\, Munich (DE)\; A. Köberle\, Innsbruck (AT)\; C. Ohnmacht\, Munich (DE)\; P. Murray\, Munich (DE)\n\nRole of SHP-2 and PD-1 in lymphoid and myeloid antitumor responses.\nReferent(s): I. Buzzago\, Bellinzona (CH)\; P. Ventura\, Bellinzona (CH)\; H. Javanmard Khameneh\, Bellinzona (CH)\; A. Zenobi\, Bellinzona (CH)\; F. Silini\, Bellinzona (CH)\; L. Brossay\, Providence (US)\; G. Guarda\, Bellinzona (CH)\n\nProbing Monoclonal Antibodies for Targeted Alzheimer&rsquo\;s Vaccine Design\nReferent(s): A. C. Vogt\, Bern (CH)\; M. Vogel\, Bern (CH)\; M. Jendrach\, Berlin (DE)\; A. Förster\, Berlin (DE)\; A. Haake\, Berlin (DE)\; C. Wong\, Berlin (DE)\; A. Zeltins\, Riga (LV)\; F. Heppner\, Berlin (DE)\; M. Bachmann\, Bern (CH)\n\nRole of type 1 IFN signaling in trained type 2 immunity\nReferent(s): E. Ben Salah\, Epalinges (CH)\; S. Bohnacker\, Epalinges (CH)\; B. Spitzlberger\, Munich (DE)\; F. Alessandrini\, Munich (DE)\; M. Kulagin\, Lausanne (CH)\; J. Esser-Von-Bieren\, Lausanne (CH)\; F. Hartung\, Munich (DE)\n\nTCR\, WHERE ARE YOU? AN INTRIGUING CASE OF A PATIENT WITH AN ABERRANT T LYMPHOCYTE POPULATION OF CD3+/CD4-/CD8-/TCR&alpha\;&beta\;-/TCR&gamma\;&delta\;- AND IGG2 DEFICIENCY\nReferent(s): C. Ballerini\, Milano (IT)\n\nHarnessing lymphatic endothelial cells to improve anti-tumor immunity&nbsp\;\nReferent(s): M. Madec\, Geneva (CH)\; L. Garnier\, Geneva (CH)\; S. Hugues\, Genève (CH)\; J. Angelillo\, Geneva (CH)\n\nTowards deciphering how inflammatory response to biomaterials modulates bone formation\nReferent(s): S. Ardicli\, Davos Wolfgang (CH)\; S. Wawrocki\, Davos Wolfgang (CH)\; H. Babayev\, Davos Wolfgang (CH)\; E. I. Bektas\, Davos (CH)\; O. Ardicli\, Davos Wolfgang (CH)\; Y. Pat\, Davos Wolfgang (CH)\; B. Rückert\, Davos Wolfgang (CH)\; A. Heider\, Davos Wolfgang (CH)\; Z. Zhou\, Guangzhou (CN)\; M. D'este\, Davos (CH)\; E. Della Bella\, Davos (CH)\; T. Serra\, Davos (CH)\; C. Ligorio\, Nottingham (GB)\; A. Mata\, Nottingham (GB)\; M. Akdis\, Davos Wolfgang (CH)\; M. Stoddart\, Davos (CH)\; C. Akdis\, Davos Wolfgang (CH)\; D. Yazici\, Davos (CH)\n\nNo Grass Pollen Allergy in sub-Saharan Africa? Analysis of Sensitization Patterns to Pollen in Swiss &amp\; sub-Saharan African Atopic Dermatitis Patients\nReferent(s): D. Fehr\, Zurich (CH)\; M. Rentschler\, Zurich (CH)\; F. Sendrasoa\, Antananarivo (MG)\; N. Li\, Zurich (CH)\; A. White\, Zurich (CH)\; C. Clemens\, Zurich (CH)\; C. Lang\, Zürich (CH)\; J. E. Masenga\, Moshi (TZ)\; N. Mosha\, Moshi (TZ)\; G. Semango\, Moshi (TZ)\; T. Rasamoelina\, Antananarivo (MG)\; A. H. Soankasina\, Antananarivo (MG)\; F. Rapelanoro Rabenja\, Antananarivo (MG)\; D. Mavura\, Moshi (TZ)\; G. Masenga\, Moshi (TZ)\; P. Schmid-Grendelmeier\, Zurich (CH)\; M. C. Brüggen\, Zurich (CH)\n\nControl of dendritic cell dynamics in the skin by the sympathetic nervous system\nReferent(s): V. Oliva\, Genève (CH)\; R. Pick\, Genève (CH)\; C. Scheiermann\, Genève (CH)\n\nAssociation of TNF-&alpha\; -308A/G SNP with kidney allograft rejection in Algerian population\nReferent(s): R. Raache\, Algiers (DZ)\; A. Chebine\, Alger (DZ)\; H. Amroun\, Alger (DZ)\; C. Touil-Boukoffa\, Alger (DZ)\; N. Attal\, Alger (DZ)\; A. Benziane\, Alger (DZ)\n\nCharacterization of adjuvants for optimal time-of-day effects of vaccines\nReferent(s): Z. M. Gul\, Geneva (CH)\; C. Scheiermann\, Genève (CH)\n\nT-Cell Receptor Precision Editing of Regulatory T-Cells for Celiac Disease\nReferent(s): R. Porret\, Lausanne (CH)\; A. Alcaraz-Serna\, Lausanne (CH)\; B. Peter\, Lausanne (CH)\; M. Hafezi\, Lausanne (CH)\; J. Bernier-Latmani\, Lausanne (CH)\; F. Du Pré\, Oslo (NO)\; O. Alfageme-Abelló\, Lausanne (CH)\; L. Ermellino\, Lausanne (CH)\; E. Lana\, Lausanne (CH)\; R. Cecchin\, Lausanne (CH)\; D. Golshayan\, Lausanne (CH)\; D. Velin\, Lausanne (CH)\; J. Eyquem\, San Francisco (US)\; Q. Tang\, San Francisco (US)\; T. Petrova\, Lausanne (CH)\; G. Coukos\, Lausanne (CH)\; M. Irving\, Lausanne (CH)\; C. Pot\, Lausanne (CH)\; G. Pantaleo\, Lausanne (CH)\; L. Sollid\, Oslo (NO)\; Y. Muller\, Lausanne (CH)\n\nCutting-Edge: Unleashing the Potential of &gamma\;&delta\; T Cells with Novel Nanoparticles for Cancer Immunotherapy Applications\nReferent(s): A. Solé Casaramona\, Bern (CH)\; M. O.mohsen\, Bern (CH)\; R. Josi\, Bern (CH)\; A. Ogrina\, Riga (LV)\; I. Balke\, Riga (LV)\; S. Marar\, Bern (CH)\; S. de Brot\, Bern (CH)\; E. Sevick\, Houston\, (US)\n\nDecoding polygenetic complexity in primary immunodeficiency\nReferent(s): A. A. Martí I Líndez\, Cambridge (GB)\; C. Hess\, Basel (CH)\; K. Patommel\, Cambridge (GB)\; O. Omarjee\, Cambridge (GB)\; B. Wingham\, Amsterdam (NL)\; D. Lau\, Oxford (GB)\; T. Elliott\, Oxford (GB)\; J. Lötscher\, Basel (CH)\; T. Kuijpers\, Amsterdam (NL)\; J. Edwards-Hicks\, Edinburgh (GB)\n\nMetal allergies &ndash\; an investigation of sensitization and allergy patterns in patients treated at the University Hospital of Z&uuml\;rich 2011-2022 &nbsp\;\nReferent(s): T. El Saadany\, Zürich (CH)\; B. Illi\, Zürich (CH)\; P. Schenk\, Uster (CH)\; P. Furrer\, Zürich (CH)\; S. Fucentese\, Zürich (CH)\; N. Li\, Zurich (CH)\; P. Schmid-Grendelmeier\, Zurich (CH)\; C. Lang\, Zürich (CH)\; K. Bärenfaller\, Davos (CH)\; D. Zhakparov\, Davos (CH)\; M. C. Brüggen\, Zurich (CH)\n\n
END:VEVENT
END:VCALENDAR